This was successfully posted to your pofile.
This box will close automatically in a few seconds. Close this window
We don't have an e-mail address on file for you. To use AAFP Connection, you must have an e-mail address in our records. Click Here
Birth Defects Linked to Fluconazole Prompt Change in Pregnancy Category
High Doses of Drug in First Trimester Pose Risk, Says FDA
By News Staff
The FDA said in an Aug. 3 safety announcement that those risks do not appear to be associated with the single 150-mg dose of fluconazole that is used to treat vaginal candidiasis. When used for that indication, the drug retains its category C designation, which means there are no adequate studies in humans, and, although studies of animals have shown an adverse effect on the fetus, potential benefits may warrant use of the drug in pregnant women despite potential risks.
In addition to vaginal candidiasis, fluconazole is used to treat yeast infections of the mouth, throat, esophagus, and other organs, as well as coccidioidal meningitis.
The FDA issued the following information for physicians:
- Published case reports describe a rare pattern of distinct congenital anomalies in infants exposed in utero to high-dose fluconazole during the first trimester.
- The features seen in affected infants include brachycephaly, abnormal facies, abnormal calvarial development, cleft palate, femoral bowing, thin ribs and long bones, arthrogryposis, and congenital heart disease.
- If fluconazole is used during pregnancy, or if a patient becomes pregnant while taking fluconazole, the patient should be informed of the potential risks.
- Adverse events involving fluconazole should be reported to the FDA's MedWatch program.